MedPacto, Inc. (KOSDAQ: 235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,150.00
+10.00 (0.16%)
Sep 12, 2024, 9:03 AM KST
-57.23%
Market Cap 205.85B
Revenue (ttm) n/a
Net Income (ttm) -27.75B
Shares Out 33.58M
EPS (ttm) -1,010.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,112
Open 6,160.00
Previous Close 6,140.00
Day's Range 6,150.00 - 6,250.00
52-Week Range 6,090.00 - 17,240.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 11, 2024

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Seong-Jin Kim
Employees 57
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.